...
hura-img

TuHURA BionSciences Inc , Common Stock

HURA

NAQ

$4.48

+$0.48

(12%)

1D
Sector: Healthcare

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$141.65M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.16M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.83 L
$14.6 H
$4.48

About TuHURA BionSciences Inc , Common Stock

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA). more

Sector: Healthcare

Returns

Data is not properly formatted.

Financials

Jun '21Jun '22Jun '23Jun '24
Total Revenue----[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Cost of Revenue32.00K---[{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Gross Profit(32.00K)---[{"date":"2021-06-30","value":-3200000,"profit":false},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Gross Margin----[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Operating Expenses21.54M7.25M9.93M29.76M[{"date":"2021-06-30","value":72.37,"profit":true},{"date":"2022-06-30","value":24.37,"profit":true},{"date":"2023-06-30","value":33.37,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Operating Income(21.57M)(7.25M)(9.93M)(29.76M)[{"date":"2021-06-30","value":-2157200000,"profit":false},{"date":"2022-06-30","value":-725498100,"profit":false},{"date":"2023-06-30","value":-993385100,"profit":false},{"date":"2024-06-30","value":-2976472000,"profit":false}]
Total Non-Operating Income/Expense-(390.81K)623.69K518.88K[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":-62.66,"profit":false},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":83.2,"profit":true}]
Pre-Tax Income(38.30M)(7.02M)(9.37M)(29.32M)[{"date":"2021-06-30","value":-3829800000,"profit":false},{"date":"2022-06-30","value":-701650900,"profit":false},{"date":"2023-06-30","value":-936751300,"profit":false},{"date":"2024-06-30","value":-2931682600,"profit":false}]
Income Taxes---(1.00)[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":-100,"profit":false}]
Income After Taxes---(29.32M)[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":-2931682500,"profit":false}]
Income From Continuous Operations-(7.02M)(9.37M)(29.32M)[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":-701650900,"profit":false},{"date":"2023-06-30","value":-936751300,"profit":false},{"date":"2024-06-30","value":-2931682600,"profit":false}]
Income From Discontinued Operations----[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Net Income(38.30M)(7.02M)(9.37M)(29.32M)[{"date":"2021-06-30","value":-3829800000,"profit":false},{"date":"2022-06-30","value":-701650900,"profit":false},{"date":"2023-06-30","value":-936751300,"profit":false},{"date":"2024-06-30","value":-2931682500,"profit":false}]
EPS (Diluted)(3.46K)(979.26)(328.34)-[{"date":"2021-06-30","value":-346177.6,"profit":false},{"date":"2022-06-30","value":-97926.21,"profit":false},{"date":"2023-06-30","value":-32834.25,"profit":false},{"date":"2024-06-30","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

HURA
Cash Ratio 1.34
Current Ratio 1.54

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HURA
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HURA
Debt Ratio Lower is generally better. Negative is bad. 0.59
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.41

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HURA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 119.45
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is TuHURA BionSciences Inc share price today?

TuHURA BionSciences Inc (HURA) share price today is $4.48

Can Indians buy TuHURA BionSciences Inc shares?

Yes, Indians can buy shares of TuHURA BionSciences Inc (HURA) on Vested. To buy TuHURA BionSciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HURA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of TuHURA BionSciences Inc be purchased?

Yes, you can purchase fractional shares of TuHURA BionSciences Inc (HURA) via the Vested app. You can start investing in TuHURA BionSciences Inc (HURA) with a minimum investment of $1.

How to invest in TuHURA BionSciences Inc shares from India?

You can invest in shares of TuHURA BionSciences Inc (HURA) via Vested in three simple steps:

  • Click on Sign Up or Invest in HURA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in TuHURA BionSciences Inc shares
What is TuHURA BionSciences Inc 52-week high and low stock price?

The 52-week high price of TuHURA BionSciences Inc (HURA) is $14.6. The 52-week low price of TuHURA BionSciences Inc (HURA) is $2.83.

What is TuHURA BionSciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of TuHURA BionSciences Inc (HURA) is

What is TuHURA BionSciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of TuHURA BionSciences Inc (HURA) is 119.45

What is TuHURA BionSciences Inc dividend yield?

The dividend yield of TuHURA BionSciences Inc (HURA) is 0.00%

What is the Market Cap of TuHURA BionSciences Inc ?

The market capitalization of TuHURA BionSciences Inc (HURA) is $141.65M

What is TuHURA BionSciences Inc ’s stock symbol?

The stock symbol (or ticker) of TuHURA BionSciences Inc is HURA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top